World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Compounding pharmacies must now cease producing their own versions of Zepbound/Mounjaro within a set time period. HealthDay ...

Lilly, for its part, has resolved its Mounjaro and Zepbound shortages, according to the FDA. Coyle pointed to moves such as Novo’s recent Wegovy launch in China, plus its efforts to push back ...

Tirzepatide is the active ingredient in the FDA-approved versions of the drug, Mounjaro and Zepbound, which are made by the pharmaceutical manufacturer Eli Lilly. Compounded tirzepatide has the ...

tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...